Order Article Reprints

Kutlu Y, Dae SA, Yilmaz F, Erdem D, Sendur MAN, Akbas S, Senocak Tasci E, Bas O, Dane F, Sakin A, et al. Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study. Cancers. 2024; 16(12):2251. https://doi.org/10.3390/cancers16122251

Kutlu, Yasin, Shute Ailia Dae, Feride Yilmaz, Dilek Erdem, Mehmet Ali Nahit Sendur, Sinem Akbas, Elif Senocak Tasci, Onur Bas, Faysal Dane, Abdullah Sakin, and et al. 2024. "Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study" Cancers 16, no. 12: 2251. https://doi.org/10.3390/cancers16122251

Kutlu, Y., Dae, S. A., Yilmaz, F., Erdem, D., Sendur, M. A. N., Akbas, S., Senocak Tasci, E., Bas, O., Dane, F., Sakin, A., Kaya, A. O., Aykan, M. B., Ergun, Y., Biter, S., Disel, U., Korkmaz, M., Selcukbiricik, F., Kose, F., Olmez, O. F., ... Yalcin, S. (2024). Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study. Cancers, 16(12), 2251. https://doi.org/10.3390/cancers16122251